https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-10-22 / Cancer Immunol. Immunother. 2012 May;61(5):629-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-10-22 / Cancer Immunol. Immunother. 2012 May;61(5):629-412011-10-22 00:00:002019-02-15 08:52:17Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-10-20 / J Transl Med 2011 Oct;9:178
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-10-20 / J Transl Med 2011 Oct;9:1782011-10-20 00:00:002019-02-15 08:50:33Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-10-18 / Int. Immunopharmacol. 2011 Dec;11(12):2200-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-10-18 / Int. Immunopharmacol. 2011 Dec;11(12):2200-72011-10-18 00:00:002019-02-15 08:47:45Improved efficacy of therapeutic vaccination with dendritic cells pulsed with tumor cell lysate against hepatocellular carcinoma by introduction of 2 tandem repeats of microbial HSP70 peptide epitope 407-426 and OK-432
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-10-15 / Immunopharmacol Immunotoxicol 2012 Jun;34(3):465-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-10-15 / Immunopharmacol Immunotoxicol 2012 Jun;34(3):465-92011-10-15 00:00:002019-02-15 08:46:01Induction of tolerogenic dendritic cells by IL-6-secreting CT26 colon carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-10-04 / Int. J. Oncol. 2012 Jan;40(1):287-98
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-10-04 / Int. J. Oncol. 2012 Jan;40(1):287-982011-10-04 00:00:002021-11-15 16:58:12Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-10-03 / Eur. Urol. 2012 Feb;61(2):290-306
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-10-03 / Eur. Urol. 2012 Feb;61(2):290-3062011-10-03 00:00:002019-02-15 08:52:46Current vaccination strategies for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-10-01 / Expert Rev Vaccines 2011 Oct;10(10):1355-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-10-01 / Expert Rev Vaccines 2011 Oct;10(10):1355-72011-10-01 00:00:002019-02-15 08:53:13Proving the principle: dendritic cell-based vaccines in urogenital cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-09-28 / Clin. Dev. Immunol. 2011;2011:249281
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-09-28 / Clin. Dev. Immunol. 2011;2011:2492812011-09-28 00:00:002020-01-08 10:10:19Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-09-19 / Strahlenther Onkol 2011 Oct;187(10):619-25
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-09-19 / Strahlenther Onkol 2011 Oct;187(10):619-252011-09-19 00:00:002011-09-19 00:00:00Regional hyperthermia combined with chemoradiotherapy in primary or recurrent locally advanced pancreatic cancer : an open-label comparative cohort trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-09-17 / Cancer Immunol. Immunother. 2012 Mar;61(3):373-84
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-09-17 / Cancer Immunol. Immunother. 2012 Mar;61(3):373-842011-09-17 00:00:002019-02-15 08:52:16A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients
